Alexander von Gabain
'Alexander von Gabain', PhD, is known for his work in Molecular microbiology and vaccine development. He is also an entrepreneur in the biotech industry. His contributions to basic and translational biomedical research are documented by a large number of publications, book chapters, edition of books,[1] patents[2][3][4]
Biography
von Gabain obtained his PhD. in Genetics at the University of Heidelberg and held a post-doctorate position at the Stanford University from 1979 to 1982.
In the 1980s and 1990s, he was Professor at the University of Umeå and at the Karolinska Institute in Stockholm, Sweden, as well as an advisor to pharmaceutical and biotech companies.
Intercell
von Gabain co-founded Intercell AG in 1998, led the company until it was successfully floated on the Vienna Stock Exchange in 2005[5] and continued as Chief Scientific Officer in the Executive Board until 2009.[6] In 2011, he was appointed to serve the Company as member of the Supervisory Board (www.intercell.com).
During his executive years, the firm succeeded to globally register and launch a novel vaccine against Japanese Encephalitis.[7] Additionally, he has accompanied further biotech enterprises in various functions. His entrepreneurial and scientific knowledge in the innovation arena has been recruited into organisations fostering entrepreneurial innovation; in 2003 into the Technology Seed Fond of the University and Technical University in Vienna, Inits (www.inits.at), of which he is chairing the supervisory Board,[8] and in 2008 into the Governing Board of the European Institute of Innovation and Technology (EIT).[9] In 2011, he was elected to become the Chairman of the EIT Governing Board (www.eit.europa.eu).[10]
From 1992 to 1998, he was chair of Microbiology of the University of Vienna and engaged in building the public private partnership of the Campus Vienna Biocenter[11] at IMP.[12]
He has academic appointments as professor at the Max F. Perutz Laboratories of the University of Vienna ([www.mfpl.ac.at]) and foreign adjunct professor at the Karolinska Institute in Stockholm, and he is a member of the Swedish Royal Academy of Engineering Science.
References
- ^ "PubMed Central® (PMC)". ncbi.nlm.nih.gov/pmc/. Retrieved 18 February 2013.
- ^ "European Patent Office". epo.org. Retrieved 18 February 2013.
- ^ "The United States Patent and Trademark Office". uspto.gov. Retrieved 18 February 2013.
- ^ "Vienna Vaccines - Networking Excellence (28-30 April 2011)". viennavaccines.com. Retrieved 18 February 2013.
- ^ "Vienna Stock Exchange". wienerborse.at. Retrieved 18 February 2013.
- ^ "Bloomberg Businessweek". investing.businessweek.com. Retrieved 18 February 2013.
- ^ "Japanese Encephalitis Vaccine". intercell.com. Archived from the original on 28 January 2013. Retrieved 18 February 2013.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ "INiTS - Innovation into Business". inits.at. Retrieved 18 February 2013.[permanent dead link]
- ^ "European Institute of Innovation and Technology". eit.europa.eu. Archived from the original on 19 January 2013. Retrieved 18 February 2013.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ "European Institute of Innovation and Technology". eit.europa.eu. Archived from the original on 19 January 2013. Retrieved 18 February 2013.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ [1]
- ^ [2]